Literature DB >> 17662009

Predictive value of clinical characteristics for 'benign' multiple sclerosis.

G S M Ramsaransing1, J De Keyser.   

Abstract

We studied a cohort of 496 patients who had multiple sclerosis (MS) for at least 10 years. Ten years after disease onset, 151 had benign MS defined as an Extended Disability Status Scale (EDSS) < or =3. Between benign and non-benign patients we compared gender, age at clinical onset, relapsing-remitting or primary progressive, symptoms at onset, recovery from first relapse, time between first and second relapse, number of relapses in the first 5 years, use of immunomodulatory drugs, and EDSS scores at 2, 5 and 10 years. A multivariate regression analysis showed that a relapsing-remitting course, a low EDSS score at 5 years, and a low number of relapses in the first 5 years were predictive for benign MS at 10 years. Other factors had no additional value. Thirty-five of the 51 patients (69%) with benign MS at 10 years were still benign at 20 years. A low 10-year EDSS score was the only clinical variable associated with a benign course at 20 years. Our results suggest that within the first 5 years from onset it is not possible to predict a benign course. Disease course, EDSS score and relapse rate at 5 years are predictors for benign MS at 10 years.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662009     DOI: 10.1111/j.1468-1331.2007.01810.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

1.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 2.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 3.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

4.  Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Authors:  Arianna Sartori; Mohammad Abdoli; Mark S Freedman
Journal:  J Neurol       Date:  2017-04-17       Impact factor: 4.849

5.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

6.  Experimental Autoimmune Encephalomyelitis Ameliorated by Passive Transfer of Polymerase 1-Silenced MOG35-55 Lymphatic Node Cells: Verification of a Novel Therapeutic Approach in Multiple Sclerosis.

Authors:  R Zilkha-Falb; M Gurevich; A Achiron
Journal:  Neuromolecular Med       Date:  2017-07-28       Impact factor: 3.843

7.  Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis.

Authors:  Piotr Sowa; Gro Owren Nygaard; Atle Bjørnerud; Elisabeth Gulowsen Celius; Hanne Flinstad Harbo; Mona Kristiansen Beyer
Journal:  Neuroradiology       Date:  2017-06-05       Impact factor: 2.804

8.  Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Authors:  Seyed Mohammad Masood Hojjati; Seyyed Ali Hojjati; Mobina Baes; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2014

9.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

10.  Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.

Authors:  Anat Achiron; Anna Feldman; David Magalashvili; Mark Dolev; Michael Gurevich
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.